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Background: How to efficiently diagnose tetrahydrobiopterin (BH4) responsiveness in patients with
phenylketonuria remains unclear. This study investigated the positive predictive value (PPV) of the 48-hour BH4
loading test and the additional value of genotype.
Methods: Data of the 48-hour BH4 loading test (20 mg BH4/kg/day) were collected at six Dutch university
hospitals. Patients with ≥30% phenylalanine reduction at ≥1 time points during the 48 hours (potential responders)
were invited for the BH4 extension phase, designed to establish true-positive BH4 responsiveness. This is defined as
long-term ≥30% reduction in mean phenylalanine concentration and/or ≥4 g/day and/or ≥50% increase of natural
protein intake. Genotype was collected if available.
Results: 177/183 patients successfully completed the 48-hour BH4 loading test. 80/177 were potential responders
and 67/80 completed the BH4 extension phase. In 58/67 true-positive BH4 responsiveness was confirmed (PPV
87%). The genotype was available for 120/177 patients. 41/44 patients with ≥1 mutation associated with long-term
BH4 responsiveness showed potential BH4 responsiveness in the 48-hour test and 34/41 completed the BH4
extension phase. In 33/34 true-positive BH4 responsiveness was confirmed. 4/40 patients with two known putative
null mutations were potential responders; 2/4 performed the BH4 extension phase but showed no true-positive
BH4 responsiveness.
Conclusions: The 48-hour BH4 loading test in combination with a classified genotype is a good parameter in
predicting true-positive BH4 responsiveness. We propose assessing genotype first, particularly in the neonatal
period. Patients with two known putative null mutations can be excluded from BH4 testing.
Keywords: Phenylketonuria, PKU, Tetrahydrobiopterin, Sapropterin dihydrochloride, Pharmacological chaperone,
Genotype, Loading testIntroduction
In phenylketonuria (PKU, OMIM 261600), deficiency of
the enzyme phenylalanine hydroxylase (PAH) leads to
increased phenylalanine (Phe) concentrations. Untreated,
this results in progressive and irreversible cerebral dam-
age [1,2]. For almost 60 years, a life-long low-Phe diet* Correspondence: k.anjema@umcg.nl
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reproduction in any medium, provided the orhas been the only possible treatment for PKU. Dietary
treatment has proved to be very effective in preventing
the devastating consequences of PAH deficiency when
started early in life (e.g. after neonatal screening). The
cognitive outcome strongly depends on optimal meta-
bolic control [3,4]. Unfortunately, adherence to such a
diet proves difficult [5].
A pharmaceutical formulation of tetrahydrobiopterin
(BH4), the natural co-factor and co-substrate of PAH, is
now an FDA and EMA-registered drug (sapropterin
dihydrochloride; Kuvan®) and provides a new treatmentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pharmacological chaperone by stabilizing PAH [6]. In
BH4-responsive patients, BH4 decreases the blood Phe
concentration and/or increases the dietary Phe tolerance
[7,8]. Correct and efficient identification of BH4-responsive
patients is important, both to improve the fast assess-
ment, as well as to avoid false expectations and un-
necessary costs. Unfortunately, there is still no golden
standard on how to assess BH4 responsiveness most
efficiently.
Three methods have been proposed for the prediction
of BH4 responsiveness: the 7–28 days BH4 challenge
[9,10], the 48-hour BH4 loading test [11] and, the START
(sapropterin therapy actual response test) BH4 challenge
and genotyping protocol [12]. Genotype was frequently
reported to be useful in predicting or excluding BH4 re-
sponsiveness [8,13-15]. However, only small studies have
correlated genotype data with in vivo BH4 challenge tests
and long-term BH4 responsiveness [16-29].
To improve the assessment of BH4 responsiveness, we
investigated the positive predictive value (PPV) of the
48-hour BH4 loading test and additional value of geno-
type for BH4 responsiveness in a large cohort of Dutch
PAH-deficient patients.
Methods
Subjects and protocol
In a national collaborative study, data were collected
from 183 patients who participated in the 48-hour BH4
loading test between November 2009 and December
2010 in six Dutch university medical centres. Following
the European Medicines Agency (EMA) and the Dutch
regulations on BH4 prescriptions, only patients above
four years of age, requiring a Phe restricted diet, and not
pregnant or planning a pregnancy were considered for
treatment with BH4. The 48-hour BH4 loading test was
also performed in younger children. The protocol
consisted of two parts: the 48-hour BH4 loading test to
assess ‘potential BH4 responsiveness’ and the BH4 ex-
tension phase to establish ‘true-positive BH4 responsive-
ness’. The BH4 protocol (the 48-hour BH4 loading test
and the BH4 extension phase) was considered standard
patient care by the Medical Ethical Committee of the
University Medical Center Groningen.
The 48-hour BH4 loading test was largely based on
recommendations made by the European working group
on PKU [11], requiring baseline Phe concentrations over
400 μmol/L. Dutch treatment guidelines recommend
blood Phe concentrations of 120–360 μmol/L in patients
under twelve years of age and 120–600 μmol/L in pa-
tients over twelve years of age [30]. Therefore, well-
controlled patients with Phe concentrations within the
recommended range had to be supplemented with diet-
ary Phe (L-Phe in powder, a protein rich supplementbased on milk protein, or an increase in natural protein
intake) to reach a stable Phe concentration ‘just’ over
400 μmol/L. The extra Phe intake was used until the test
was finished. Typically, multiple blood samples were
taken to assure stable Phe concentrations. Patients with
Phe concentrations above 400 μmol/L were instructed to
continue their usual diet. All patients received 20 mg/kg
BH4 (sapropterin dihydrochloride; Kuvan®) twice, dir-
ectly after blood sampling at baseline (T = 0) and after
24 hours (T = 24). BH4 dosages were rounded up or
down to the nearest 100 mg. Blood samples were col-
lected after T = 0, 8, 16, 24 and 48 hours. Patients with a
30% or more reduction in blood Phe concentration at
one or more points compared to the baseline (T = 0)
were regarded as ‘potential BH4-responsive’ and were in-
vited for the BH4 extension phase.
The BH4 extension phase consisted of three steps in
which the blood Phe concentrations, which were mea-
sured one to three times a week, had to remain within
the ranges of the guideline. Beforehand, a three-day diet-
ary record was used to determine baseline Phe tolerance.
BH4 was then introduced at 20 mg/kg/day, followed by:
an increase of dietary Phe (to reach the maximal Phe tol-
erance), BH4 dose adjustment (decrease if possible) and
finally adjustment to the Phe-free amino acid supple-
ment according to the patients’ total protein needs (age
and sex dependent). Following this last step, if blood
Phe concentrations exceeded the upper target limit, both
the BH4 dose and the amount of Phe intake were re-
evaluated. Different methods were used to increase diet-
ary Phe (natural protein or L-Phe powder/protein rich
supplement first), but in all cases this was done grad-
ually and on an individual basis. The method to deter-
mine the maximum Phe tolerance was not protocolized,
although it was advised to keep or bring the Phe concen-
trations within treatment range. Typically, when Phe
levels were above the target concentration, natural pro-
tein intake was decreased by 10-20% depending on the
amount of increase in Phe concentration and the abso-
lute concentration. The reduction of the Phe-free amino
acid supplement was performed in multiple steps in case
of large quantities. When the patients had Phe concen-
trations within target range or were stabile, a three-day
dietary record was used to determine the final Phe toler-
ance and dietary sufficiency for all nutrients. Dietary re-
cords were analysed by nutritionists qualified in
metabolic diseases at the various centres. True-positive
BH4 responsiveness was defined as a 30% or more re-
duction in blood Phe concentration compared to mean
blood Phe concentrations prior to the 48-hour BH4
loading test with the same diet, and/or an increase in
dietary Phe tolerance of ≥50% or ≥4 grams of natural
protein without increasing the Phe concentrations above
the upper target.
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Blood Phe concentrations in dried blood spots were
measured by the patients’ respective centre laboratory
according to standard quantitative methods, with the
same method per patient. To calculate the individual
mean blood Phe concentration prior to the BH4 intro-
duction, all known values from the year preceding the
BH4 loading test were used, with a minimum of four
measurements; alternatively, the period was extended to
two years or this value was considered missing. The in-
dividual mean blood Phe concentration after the BH4
extension phase was calculated from all the Phe concen-
trations in the first three months after finishing the BH4
extension phase, with a minimum of four measurements.
The period was extended until four samples were avail-
able in patients that did not send that many samples
(maximum one year). Weight was usually measured at
the first day of the BH4 loading test or at a recent out-
patient visit, to determine the total daily dose of BH4.
Otherwise, the most recent value was used. The medical
history was obtained to ascertain the blood Phe concen-
tration at diagnosis. Data on genotype were collected if
available. A Medline database literature search was
performed to compose a list of mutations associated
with long-term BH4 responsiveness. This list consisted
of thirty mutations. Mutations with a known residual
in vitro activity of ≤1%, all nonsense mutations, vari-
ants altering the reading frame and splice-site muta-
tions leading to exon skipping and disruption of the
reading frame were regarded putative null mutations
[13,14,20]. All genotypes are tabulated in the BIOPKUFigure 1 Study profile.database (www.biopku.org) and compared with existing
information.Statistical analysis
Normality was defined according to the Shapiro Wilk
test. As almost all data showed skewed distributions,
data are presented as medians with inter-quartile ranges
(IQR). The Mann–Whitney U test was used to compare
independent continuous data. To compare related con-
tinuous data the Wilcoxon Signed Rank test was used.
The Chi-square test was used for categorical data unless
the minimum expected count was smaller than five, in
which case Fisher’s exact test was used. Statistical analyses
were performed using PASW statistics version 18.0.3,
SPSS, Inc., Chicago, IL, USA. A two-tailed P-value < 0.05
was assumed as statistically significant.Results
Cohort
A total of 183 patients started the 48-hour BH4 loading test.
Six patients were excluded because of illness, missing T = 48
blood sample or irregular BH4 administration (Figure 1).
The median (IQR) age of the 177 patients that successfully
completed the 48-hour loading test was 13.8 (8.6-21.1) years.
Seven children were younger than four years old during the
48-hour BH4 loading test, but none during the BH4 exten-
sion phase. A female gender accounted for 52.5% of the
study population. Phe was supplemented in 51 out of 66 pa-
tients younger than 12 years old and in 36 out of 111 pa-
tients of 12 years or older.
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In the 48-hour BH4 loading test, 80 out of 177 (45.2%)
patients were potentially BH4-responsive. Out of 80 pa-
tients with potential BH4 responsiveness, 67 (85%)
started the BH4 extension phase. False-positive BH4 re-
sponsiveness was shown in nine of them. Therefore, the
PPV of the 48-hour BH4 loading test was 87%. Demo-
graphic and clinical details of all patients with no poten-
tial BH4 responsiveness, false-positive and true-positive
BH4 responsiveness as well as potentially responsive pa-
tients who did not participate in the BH4 extension
phase are shown in Table 1.
In patients with a 30-40% decrease in Phe concentra-
tions (n = 18), the PPV was 67%, while this was 94% in
patients with ≥40% reduction (n = 49), P = 0.009. The
PPV of patients responding only at T = 48 (n = 11) was
lower than patients who respond within 24 hours (n =
56) (PPV 64% and 91% respectively, P = 0.03). Patients
who responded within 24 hours showed a median (IQR)
Phe concentration decrease of 56 (42 – 57) percent at
the 24 hour time point, whereas this was 24 (16 – 26)
percent in patient who responded only at T = 48. At T =
48 this was 50 (35 – 68) and 36 (34 – 45) percent, re-
spectively. Patients with at least 30% decrease in Phe
concentration at two or more moments showed true
BH4 responsiveness in 47 out of 50, whilst this was ten
out of 16 in patients with only one moment. Five pa-
tients had this one moment at another time point than
T = 48, of them 3 showed true BH4 responsiveness.Table 1 Demographic and clinical details of patients with non
BH4 loading test: Non-potential BH4-responsive (n = 97)
BH4 extension phase:
Sex
Male 47 (48.5)
Female 50 (51.5)
Age (years) A* 14.7 (10.3 – 23.0)
<12 years A** 30 (30.9)
≥12 years 67 (69.1)
Baseline Phe (μmol/L)2 B*** C* 663 (530 – 915)
Mean Phe3,4 B*** C** 494 (364 – 700)
<12 years B* C** 397 (290 – 441)
≥12 years4 B*** 564 (427 – 773)
Phe at diagnosis5 B***, C***
<600 μmol/L 3 (3.5)
600–1199 μmol/L 13 (15.3)
>1200 μmol/L 69 (81.2)
Data are n (%) or median (interquartile range). 1 no BH4 extension phase. 2 Phe con
concentration prior to the BH4 loading test. 4 Missing in n = 14 (<30%), n = 10 (True
n = 12 (<30%). A) comparing non-potential BH4-responsive and false-positive, B) co
positive and true-positive. *P = <0.05, **P = <0.01, ***P = <0.001.The duration of the BH4 extension phase ranged from
six to 76 weeks in patients with true-positive BH4 re-
sponsiveness with a median of 24 weeks. During this
period a median (IQR) amount of 40 (24 – 55) blood
samples were taken per patient. For patients with a
false-positive response the duration of the BH4 exten-
sion phase was 6 to 43 weeks, with a median of 13 weeks.
In patients with true-positive BH4 responsiveness the
median (IQR) natural protein intake increased signifi-
cantly from 17 (12–28) g to 49 (34 – 57) g (P = 0.000).
The distribution of increase in natural protein is shown
in Figure 2A. In 41 patients four or more blood samples
were taken within three months after stabilization (with
a median of seven samples). Eleven patients collected
four blood samples within one year, with a mean period
of 20 ± 6.2 weeks. In six (adult) patients too little sam-
ples were collected to calculate the mean Phe concentra-
tion after stabilization of BH4 treatment. These six
patients were excluded from Phe concentration analysis.
The median (IQR) of the mean Phe concentrations in
patients with enough samples did not significantly
change (350 (250–460) μmol/L prior to BH4 treatment
and 329 (272–415) μmol/L after stabilization, P = 0.716).
The distribution of the decrease in Phe concentration is
shown in Figure 2B. An overview of changes in natural
protein as well as Phe concentration can be seen in
Figure 2C. Patients with a late response during the 48-
hour BH4 loading test and who were true BH4 responders
showed no difference in baseline natural protein intake-potential BH4 responsiveness and False/True-positives
Potential responder (n = 80)
False-positive (n = 9) True-positive (n = 58) Other1 (n = 13)
6 (66.7) 24 (41.4) 7 (53.8)
3 (33.3) 34 (58.6) 6 (46.2)
8.0 (6.4 – 11.9) 12.3 (7.7 – 17.9) 14.1 (10.4 – 19.4)
7 (77.8) 25 (43.1) 4 (30.8)
2 (22.2) 33 (56.9) 9 (69.2)
620 (528 – 831) 465 (358 – 555) 485 (386 – 590)
455 (406 – 553) 304 (244 – 401) 267 (239 – 407)
455 (372 – 539) 282 (227 – 400) 274 (207 – 318)
440, 759 (n = 2) 332 (255 – 414) 264 (239 – 456)
0 (0.0) 26 (44.8) 4 (30.8)
2 (22.2) 26 (44.8) 3 (23.1)
7 (77.8) 6 (10.3) 6 (46.2)
centration at T = 0 (with Phe loading when necessary). 3 Mean Phe
-positives) and n = 1 (Other). 5 First Phe concentration in hospital, missing in
mparing non-potential BH4-responsive and true-positive, C) comparing false-
Figure 2 Treatment results in patients with true-positive BH4
responsiveness. (A) Histogram of the increase in natural protein
intake (g/day). (B) Histogram of the percentage change in
phenylalanine concentration. (C) Combined overview of the increase
in natural protein intake (g/day) and the absolute change in
phenylalanine concentration.
Table 2 Mutations associated with true BH4
responsiveness and mutations newly associated with true
BH4 responsiveness
p.F39L p.V190A p.K320N New
p.L48S p.V230I p.L348V p.A104D
p.F55L p.R241Q p.P366H p.T193I
p.I65T p.R241H p.A373T p.P211T
p.R68S p.R241C p.E390G p.T238A
p. D129G p.V245A p.A403V p.P314H
p.P147L p..P275S p.F410S p.R408Q
p.V177L p.A300S p.Y414C
p.V177M p.A309V p.D415N
p.E178G p.A313T p.P416Q
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(Median (IQR) 13 (7 – 21) g versus 17 (12 – 29) g, re-
spectively, P = 0.211). Also the median amount of increase
was not different (24 g and 25 g of natural protein respect-
ively, P = 0.674).Genotype
Genotype was determined in 127 patients and revealed
heterozygosity in 102 patients and homozygosity in 18
patients, while only one mutation was identified in four
patients and no PAH mutations were identified in two
patients (siblings). Furthermore, one patient was found
to have a silent mutation (p.V245V) and a p.G272* mu-
tation, with no evidence of a third mutation. This patient
had a severe phenotype (diagnostic Phe concentration of
1963 μmol/L and a dietary Phe tolerance of 8.1 mg/kg/
day) and was potentially BH4-responsive (47% Phe re-
duction), but did not want to participate in the BH4 ex-
tension phase. An overview of all 120 complete
genotypes including 48-hour BH4 loading test and BH4
extension phase results is available in the Additional file 1:
Table S1. The table also shows four novel mutations of the
PAH gene. An overview of the mutations associated with
long-term BH4 responsiveness is shown in Table 2.
Thirty-five patients had a genotype consisting of two
putative null mutations, 28 a functionally hemizygous
genotype (a combination of a putative null mutation on
one allele and a mutation associated with true BH4 re-
sponsiveness on the other allele) and, three patients a
combination of two mutations associated with true BH4
responsiveness. For these patients the outcome is shown
in Figure 3.
Seven patients with true-positive BH4 responsiveness
were identified as having a genotype consisting of a pu-
tative null mutation and a mutation not yet associated
with BH4 responsiveness or a homozygous genotype
with mutations not yet associated with BH4 responsive-
ness (p.A104D, p.T193I, p.P211T, p.P314H, p.R408Q
and the novel mutation p.T238A). One or more unclas-
sified mutations including the p.R261Q and p.R158Q
mutation were detected in 47 patients. Results regarding
the 48-hour BH4 loading test and the BH4 extension
phase are shown in Table 3.
Figure 3 Outcome. The outcome of the 48-hour BH4 loading test
and the BH4 extension phase in patients with (A) 2 Putative Null
mutations (B) Compound heterozygosity (C) 2 mutations associated
with true BH4 responsiveness.
Table 3 Genotypes with unclassified mutations
No potential BH4
responsiveness (n)
Potential BH4
responsiveness (n)
c.168+5G>C1/p.R261Q (1) False positive
c.842+1G>A1/p.R243Q (1) c.1315 + 1G > A1/p.I174N (1)
c.842+5G>A1/p.R158Q (1) p.R158Q/p.R158Q (1)
c.1066-11G>A1/p.D222G (1) p.R158Q/p.Y277D (1)
c.1315+1G>A1/p.I174N (1) p.R243*1/p.R261Q (1)
c.1315+1G>A1/p.R261Q (4)
c.1315+1G>A1/p.R261P (1) True positive
c.1315+1G>A1/p.Y277D (1) p.L48S2/p.R408W (1)
c.1315+1G>A1/p.R408W (1) p.A104D3/p.R158Q (1)
p.L48S2 /p.R261Q (1) p.A104D3/p.R408W (1)
p.R111X1/p.R408W (1) p.R158Q/p.V190A2 (2)
p.R158Q/p.R158Q (1) p.R158Q/p.Y414C2 (2)
p.R158Q/p.R243*1 (1) p.I174N/p.P211T3 (1)
p.R158Q/p.R261P (1) p.E178G2/p.Y343C (1)
p.R158Q/p.R408W1 (1) p.R261Q/p.P281L1,4 (1)
p.I174T/p.F299C1 (1) p.R261P/p.Y414C2 (1)
p.C203Y/ p.L348V2 (1) p.Y277D/p.P314H3 (1)
p.R261Q/p.R261Q (2) p.E280K/p.Y414C2 (1)
p.R261Q/p.E280K1(2) p.A300S2/p.R408W (1)
p.R261Q/p.P281L1 (1)
p.P281L1/p.R413P (2) No extension phase
p.L48S2/p.R158Q (1)
p.Y277D/p.P314H3 (1)
1 Putative Null Mutation. 2 Mutation associated with true BH4 responsiveness.
3 New Responsive Mutation. 4 Natural protein increase: 6.5 g/day
(before treatment 10.5 g/day) with no statistically significant Phe
concentration increase [6%, P = 0.379].
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to be associated with BH4 responsiveness, 41 showed
potential BH4 responsiveness (three non-potential re-
sponders: c.1066-11G>A/p.L48S 27%, p.L48S/p.R261Q
28%, p.C203Y/p.L348V 25%). Of 41 potential BH4 re-
sponders 34 patients participated in the BH4 extension
phase. Of those 34 patients with potential responsive-
ness and a favourable genotype, 33 were true respon-
sive (97%, no true BH4 responsiveness was seen in
p.I65T/p.L311P).
Discussion
This study, in a large cohort of PKU patients, shows that
the 48-hour BH4 loading test has a high PPV for true
BH4 responsiveness. Furthermore, it shows that patients
with genotypes including at least one mutation known
to be associated with long-term BH4 responsivenesshave a high rate of true response. This is the first study
to investigate the PPV for BH4 responsiveness of the
48-hour BH4 loading test and the additional value of
genotype. Establishing a reliable pre-selection method
is of high importance, since it could save time and
money, and will prevent false expectations. The treat-
ment of BH4 responsive PKU patients has been mark-
edly changed since the therapy was introduced.
Expansion of the Phe-restricted diet or even complete
liberation can reduce a major burden. Although quality
of life results obtained by standardized questionnaires
(not suitable for PKU) do not show a significant im-
provement, patients do report an increased quality of
life [27,28].
Recently, we amongst others suggested that 24 hours
is not long enough to detect patients with a delayed re-
sponse to BH4 [16,31-33]. Indeed in this study we con-
firm that patients with true BH4 responsiveness can be
missed in a 24 hour test. Other studies suggest
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[9,28,34]. We detected some patients who tend to show
a response at T = 48. However, we did not compare our
results to a longer lasting test, such as the 7–28 day
BH4 challenge. As our data indicate that patients who
show a first response at T = 48 are less likely to show
true BH4 responsiveness than patients who respond
within 24 hours, prolongation of the BH4 loading test
will possibly increase the number of patients with true
BH4 responsiveness, but will also decrease the PPV and
specificity. Also, influence of external factors increases
with the length of the test. Moreover, patients with only
one moment of response during the 48-hour BH4 load-
ing test can show true BH4 responsiveness. Another
strategy is published by Singh and Quirk. They chose
to see whether it is possible to liberalize the diet in
patients with just 15% decrease of Phe after one
month of BH4 treatment [35]. Unfortunately however,
this study does not show whether such low a cut off
results in the detection of extra BH4 responsive
patients.
As expected blood Phe concentrations at the diagno-
sis, baseline Phe concentrations and Phe concentrations
prior to the BH4 loading test were significantly lower in
patients with true-positive BH4 responsiveness than pa-
tients without potential BH4 responsiveness and false-
positives. Nevertheless, these biochemical parameters
can give an indication but show too much overlap for
practical use in predicting BH4 responsiveness. Another
notable finding was that a majority of false-positive pa-
tients are found in the younger age range. At present,
we do not have a clear explanation for this finding. Pos-
sibly, younger patients have more variability in their
blood Phe concentrations.
Since a few years it is recognized that a genotype can
be helpful in predicting BH4 responsiveness and to do
so a full genotype is required [14,15,36]. Our results
underline this assumption. Patients who have a function-
ally hemizygous genotype are frequently true BH4 re-
sponders. The three patients who were not potential
BH4 responders all reached a 20-30% Phe concentration
decrease in the 48-hour BH4 loading test and can poten-
tially also benefit from the therapy. The patients with
two mutations associated with true BH4 responsiveness
were all true BH4 responders. This concerns only three
patients as patients with this genotype combination
probably have mild hyperphenylalaninemia very often
and do not always require treatment, which was an in-
clusion criterion. Furthermore, the results in this study
support the suggestion in the literature that patients
with two putative null mutations are not candidates for
BH4 treatment [36,37]. In a recent study by Sterl et al.
the proportions of predicted BH4 responsiveness are
fairly similar to our results [38].An important remark is that a classified genotype is
needed to predict BH4 responsiveness. As more than
400 missense mutations are described and 75 to 90 per-
cent of the patients are compound heterozygous
[8,13,27], this results in a large number of as yet unclas-
sified genotypes. Additionally, some mutations are asso-
ciated with an inconsistent BH4 response, for instance
p.R158Q [8,13], p.I65T [21,26,39,40] and p.R261Q
[8,13,14,27]. In our patients, where the p.R158Q mutation
was homozygous or combined with a putative null muta-
tion, it showed no BH4 responsiveness. The p.I65T muta-
tion combined with a putative null mutation showed
potential response in two out of two patients. However,
unfortunately, one patient did not perform the BH4 exten-
sion phase (60% Phe concentration decrease) and the
other was a false-positive. The p.R261Q mutation again
showed variable results, with a response just under the
threshold of 30% remarkably often. Patients who are func-
tionally hemizygous for p.R261Q seldom show true BH4
responsiveness, but one of our patients and one patient
described by Hennermann et al. [27], both p.R261Q/L.
P281L, show (modest) long-term BH4 responsiveness.
Since this study reports patient care results, patients
without potential BH4 responsiveness did not participate
in the BH4 extension phase. This limits the conclusion
regarding its diagnostic value. Other results, however
(number of false-positives in patients with borderline re-
sponse), support the presumption that the number of
false-negatives will be limited. A possible bias in the 48-
hour BH4 loading test could be the supplementation of
Phe to increase the baseline Phe concentration and the
different methods to reach this increase. The influence
of the different metabolic kinetics is unclear [41,42].
With respect to the true BH4 responsiveness criteria,
the extra 4 g of natural protein (180 mg Phe) tolerance
increase criterion can be considered relatively modest.
This age independent criterion was agreed within the
Dutch group of metabolic physicians. If the criterion
were doubled to 8 g of natural protein, four patients
would not have met this tolerance requirement. Two out
of these four patients also showed a 30% or more de-
crease in blood Phe concentration. Of the other two pa-
tients (both children), genotype showed heterozygosity
for p.R261Q/p.P281L in one and c.1315+1G>A/p.L348V
in the other. Furthermore, we anticipated that the BH4
extension phase would take less than six months.
However, the actual duration exceeded this six months
time period in 41 percent of the patients, with three
patients taking even longer than one year. There are
several explanations for this longer duration of which
the exploration of the possible speed of Phe tolerance
increase is an important one, as is the motivation of
the patients during the last stages (especially blood
sampling frequency).
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In conclusion, notwithstanding the small number of pa-
tients, a classified genotype seems a good predictor of
BH4 responsiveness. Therefore, assessing genotype first
maybe an option, particularly in the neonatal period
when in Europe BH4 is not yet approved for use. In case
the protocol would be altered to assessing genotype first,
the 48-hour BH4 loading test is an adequate and
patient-friendly method for detecting BH4 responsive-
ness, especially for patients with an unclassified or un-
known genotype. The duration of the test is adequate
for many patients and whereas multiple time points with
≥30% Phe concentration reduction are beneficial, one
time point can indicate true BH4 responsiveness.
Additional file
Additional file 1: Table S1. Overview of genotypes, results of the 48-
hour BH4 loading test and the BH4 extension phase.
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